BBNX vs RTX · rev $100.3M vs P/E 36, rev $46.78B
Beta Bionics, Inc. Common Stock (BBNX) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Beta Bionics, Inc. Common Stock (BBNX) is a medical devices company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported BBNX revenue for 2025-12-31 was $100.3M. Net income was -$73.2M. Revenue was up 53.9% from 2024-12-31 to 2025-12-31. BBNX currently screens at market cap $640.8M.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
BBNX currently screens at market cap $640.8M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the BBNX and RTX stock pages for the full models.
Not investment advice.